Low-Calorie Diet and Exercise Prompt Diabetes Remission in Trial

Remission Rates and Weight Outcomes at Twenty-Four Weeks

A structured lifestyle intervention induced remission in 54 percent of younger adults with early-onset type 2 diabetes (EOT2D) within 24 weeks. The randomized trial enrolled 96 adults across three sites in England and Canada. Participants in the intervention arm achieved remission at a rate of 27 out of 50 individuals, compared to 2 out of 46 individuals receiving usual medical care.

Adjusted statistical models indicated that intervention participants were 21 times more likely to achieve remission than the control group. Mean baseline weight stood at 100.7 kilograms in the intervention cohort and 103.2 kilograms in the control cohort. The intervention group recorded an average weight reduction of 8.4 kilograms, compared to 1.2 kilograms in usual care.

That shift created an adjusted difference of 7.5 kilograms between the groups. Most of that extra loss, specifically 6.6 kilograms, came directly from fat mass. Final clinical assessments captured data from 86 of the original 96 enrolled individuals.

Trial Design and Caloric Restriction Protocol

The trial evaluated an open-label behavioral regimen against usual clinical care over a 24-week period. Investigators recruited men and women aged 18 to 45 years presenting with obesity and early-onset type 2 diabetes who were not receiving insulin therapy. The cohort had an average age of 38 years and a mean body mass index (BMI) of 35.2 kilograms per square meter.

Participants began a low-energy diet (LED) delivering 800 to 900 kilocalories daily with a macronutrient split of 30 percent protein, 50 percent carbohydrate, and 20 percent fat. Individuals halted all glucose-lowering drugs and blood pressure medications at baseline unless albuminuria was present. The first two weeks utilized total meal replacement formulations.

Weeks 3 through 12 retained identical caloric targets while permitting one solid meal each day alongside meal replacement products. That meal supplied 60 to 90 grams of protein, one fruit serving, and two portions of non-starchy vegetables. Patients consumed at least two liters of calorie-free fluids daily, with fiber-based laxatives supplied as needed.

Exercise Components and Remission Criteria

Remission required meeting strict biochemical and pharmaceutical thresholds after 24 weeks of participation. Investigators defined the outcome as a glycated hemoglobin (HbA1c) level below 6.5 percent (48 millimoles per mole) maintained without glucose-lowering medication for at least 12 continuous weeks. Missing clinical data were counted as non-remission events in the primary efficacy analysis.

The physical conditioning component paired dietary restriction with supervised exercise sessions during the initial 12 weeks. Participants completed two supervised sessions covering aerobic and resistance training alongside one independent session every week. Weeks 13 through 24 transitioned participants into an independent exercise program combined with an adjusted weight-maintenance diet.

Secondary endpoints measured cardiorespiratory fitness, body composition shifts, and cardiac structure across the intervention period. Researchers from McGill University in Montreal and the University of Leicester in England coordinated the study sites. The trial enrolled participants from September 24, 2021 through June 6, 2025.

Study Boundaries and Patient Population Limits

The findings apply strictly to younger adults with obesity who do not use injectable insulin. Individuals managing later-onset diabetes or those with kidney-related albuminuria require alternative medical oversight, as their safety profiles differ substantially. Rapid cessation of glucose and blood pressure medications requires direct clinical supervision to avoid acute metabolic complications.

Long-term maintenance beyond 24 weeks remains unmeasured in this primary efficacy report. Adherence to an 800 to 900 kilocalorie daily limit requires structured meal replacements and behavioral support that standard care visits rarely provide. Patients considering dietary changes should discuss medication adjustments and supervised weight programs with their personal clinician.

• Participants were aged 18 to 45 years with obesity and took no baseline insulin.
• Medication withdrawal occurred under clinical monitoring at the start of the dietary intervention.
• The trial concluded primary outcome tracking at 24 weeks across three academic medical centers.